AGL 38.70 Increased By ▲ 0.14 (0.36%)
AIRLINK 212.70 Increased By ▲ 4.93 (2.37%)
BOP 10.04 Decreased By ▼ -0.02 (-0.2%)
CNERGY 6.63 Decreased By ▼ -0.45 (-6.36%)
DCL 9.59 Decreased By ▼ -0.40 (-4%)
DFML 40.10 Decreased By ▼ -1.04 (-2.53%)
DGKC 100.39 Decreased By ▼ -3.07 (-2.97%)
FCCL 35.75 Decreased By ▼ -0.60 (-1.65%)
FFBL 89.90 Decreased By ▼ -1.69 (-1.85%)
FFL 14.15 Decreased By ▼ -0.45 (-3.08%)
HUBC 135.80 Decreased By ▼ -3.63 (-2.6%)
HUMNL 13.95 Decreased By ▼ -0.15 (-1.06%)
KEL 5.76 Decreased By ▼ -0.21 (-3.52%)
KOSM 7.28 Decreased By ▼ -0.58 (-7.38%)
MLCF 46.30 Decreased By ▼ -0.98 (-2.07%)
NBP 66.38 Decreased By ▼ -7.38 (-10.01%)
OGDC 218.97 Decreased By ▼ -3.69 (-1.66%)
PAEL 38.25 Increased By ▲ 0.14 (0.37%)
PIBTL 8.85 Decreased By ▼ -0.42 (-4.53%)
PPL 199.65 Decreased By ▼ -6.20 (-3.01%)
PRL 39.19 Decreased By ▼ -0.66 (-1.66%)
PTC 25.90 Decreased By ▼ -0.72 (-2.7%)
SEARL 105.25 Decreased By ▼ -4.99 (-4.53%)
TELE 9.10 Decreased By ▼ -0.13 (-1.41%)
TOMCL 37.50 Decreased By ▼ -0.71 (-1.86%)
TPLP 13.65 Decreased By ▼ -0.12 (-0.87%)
TREET 25.48 Decreased By ▼ -0.97 (-3.67%)
TRG 58.96 Decreased By ▼ -1.58 (-2.61%)
UNITY 33.49 Decreased By ▼ -0.65 (-1.9%)
WTL 1.74 Decreased By ▼ -0.14 (-7.45%)
BR100 12,053 Decreased By -245.5 (-2%)
BR30 37,791 Decreased By -1086.3 (-2.79%)
KSE100 112,590 Decreased By -2270.7 (-1.98%)
KSE30 35,442 Decreased By -753.7 (-2.08%)

BEIJING: Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday.

The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

It demanded that AstraZeneca China close loopholes in supervision of marketing activities, the NHSA added.

In a statement on Friday, the company said some employees in the southern city of Shenzhen had altered or participated in altering patients’ testing reports, and were suspected of medical insurance fraud.

The NHSA and public security ministry held a meeting with company officials in December to brief them on the investigation, it added.

“AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS,” it said.

An AstraZeneca spokesperson said all employees involved in the Shenzhen case were Chinese nationals.

Comments

Comments are closed.